Director/PDMR Shareholding
Oxford Biomedica plc announced that Chief Legal Officer Natalie Walter exercised 3,816 nil-cost Deferred Bonus Plan options and sold the corresponding 3,816 ordinary shares at an average price of £6.145 per share, generating £23,449.32. Similarly, Chief People Officer Lisa Doman exercised 3,564 nil-cost DBP options and sold the same number of ordinary shares at an average price of £6.145 per share, realizing £21,900.78. These transactions occurred on 22 May 2026.
Select text to share a quote on X · sign in to keep highlights & notes in your OXB notes
Oxford, UK - 22 May 2026: OXB (LSE: OXB) (the "Company"), a global quality and innovation-led cell and gene therapy CDMO, today announces that Natalie Walter, Chief Legal Officer and Group Company Secretary has exercised 3,816 Deferred Bonus Plan (DBP) options at an exercise price of £nil per share on 22 May 2026 and disposed of 3,816 ordinary shares at an average price of £6.145 per share on 22 May 2026.
In addition, Lisa Doman, Chief People Officer, exercised 3,564 Deferred Bonus Plan (DBP) options at an exercise price of £nil per share and sold 3,564 ordinary shares at an average price of £6.145 per share on 22 May 2026.
| 1. | Details of the p erson discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA") | |||||
| a) | Is this a PDMR or PCA submission | Submission for PDMR | ||||
| b) | Name of natural person | Natalie Walter | ||||
| c) | Legal person | |||||
| 2. | Reason for the notification | |||||
| a) | Position/status | Chief Legal Officer and Group Company Secretary | ||||
| b) | Initial notification/ amendment | Initial Notification | ||||
| 3. | Details of the Issuer | |||||
| a) | Full name of the entity | Oxford Biomedica plc | ||||
| b) | LEI code | 213800S1GVQNXQ15K851 | ||||
| a) | Date of the transaction | 22-May-2026 | ||||
| b) | Description of the financial instrument | Share | ||||
| c) | Identification code | ISIN: GB00BDFBVT43 | ||||
| d) | Nature of the transaction | Exercise of 3,816 DBP options | ||||
| e) | Place of the transaction | Outside the trading venue | ||||
| f) | Currency | GBP - British pound | ||||
| g) | Price(s) and volumes(s) |
| ||||
| h) | Aggregated information - Aggregate volume - Price - Aggregated total | 3,816 £0.00 £0.00 | ||||
| 1. | Details of the p erson discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA") | |||||
| a) | Is this a PDMR or PCA submission | Submission for PDMR | ||||
| b) | Name of natural person | Natalie Walter | ||||
| c) | Legal person | |||||
| 2. | Reason for the notification | |||||
| a) | Position/status | Chief Legal Officer and Group Company Secretary | ||||
| b) | Initial notification/ amendment | Initial Notification | ||||
| 3. | Details of the Issuer | |||||
| a) | Full name of the entity | Oxford Biomedica plc | ||||
| b) | LEI code | 213800S1GVQNXQ15K851 | ||||
| a) | Date of the transaction | 22-May-2026 | ||||
| b) | Description of the financial instrument | Share | ||||
| c) | Identification code | ISIN: GB00BDFBVT43 | ||||
| d) | Nature of the transaction | Sale of 3,816 ordinary shares | ||||
| e) | Place of the transaction | London Stock Exchange, Main Market (XLON) | ||||
| f) | Currency | GBP - British pound | ||||
| g) | Price(s) and volumes(s) |
| ||||
| h) | Aggregated information - Aggregate volume - Price - Aggregated total | 3,816 £6.145 £23,449.32 | ||||
| 1. | Details of the p erson discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA") | |||||
| a) | Is this a PDMR or PCA submission | Submission for PDMR | ||||
| b) | Name of natural person | Lisa Doman | ||||
| c) | Legal person | |||||
| 2. | Reason for the notification | |||||
| a) | Position/status | Chief People Officer | ||||
| b) | Initial notification/ amendment | Initial Notification | ||||
| 3. | Details of the Issuer | |||||
| a) | Full name of the entity | Oxford Biomedica plc | ||||
| b) | LEI code | 213800S1GVQNXQ15K851 | ||||
| a) | Date of the transaction | 22 May 2026 | ||||
| b) | Description of the financial instrument | Share | ||||
| c) | Identification code | ISIN: GB00BDFBVT43 | ||||
| d) | Nature of the transaction | Exercise of DBP options | ||||
| e) | Place of the transaction | Outside the trading venue | ||||
| f) | Currency | GBP - British pound | ||||
| g) | Price(s) and volumes(s) | Price(s) Volume(s) £nil 3,564 | ||||
| h) | Aggregated information - Aggregate volume - Price - Aggregated total | 3,564 £nil £nil | ||||
| 1. | Details of the p erson discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA") | |||||
| a) | Is this a PDMR or PCA submission | Submission for PDMR | ||||
| b) | Name of natural person | Lisa Doman | ||||
| c) | Legal person | |||||
| 2. | Reason for the notification | |||||
| a) | Position/status | Chief People Officer | ||||
| b) | Initial notification/ amendment | Initial Notification | ||||
| 3. | Details of the Issuer | |||||
| a) | Full name of the entity | Oxford Biomedica plc | ||||
| b) | LEI code | 213800S1GVQNXQ15K851 | ||||
| a) | Date of the transaction | 22 May 2026 | ||||
| b) | Description of the financial instrument | Share | ||||
| c) | Identification code | ISIN: GB00BDFBVT43 | ||||
| d) | Nature of the transaction | Sale of 3,564 ordinary shares | ||||
| e) | Place of the transaction | Outside the trading venue | ||||
| f) | Currency | GBP - British pound | ||||
| g) | Price(s) and volumes(s) |
| ||||
| h) | Aggregated information - Aggregate volume - Price - Aggregated total | 3,564 £6.145 £21,900.78 |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.